Nothing Special   »   [go: up one dir, main page]

PE20211095A1 - Composiciones de escherichia coli y metodos de estas - Google Patents

Composiciones de escherichia coli y metodos de estas

Info

Publication number
PE20211095A1
PE20211095A1 PE2021000227A PE2021000227A PE20211095A1 PE 20211095 A1 PE20211095 A1 PE 20211095A1 PE 2021000227 A PE2021000227 A PE 2021000227A PE 2021000227 A PE2021000227 A PE 2021000227A PE 20211095 A1 PE20211095 A1 PE 20211095A1
Authority
PE
Peru
Prior art keywords
methods
escherichia coli
compositions
modified
coli
Prior art date
Application number
PE2021000227A
Other languages
English (en)
Inventor
Robert G K Donald
Annaliesa Sybil Anderson
Laurent Oliver Chorro
Jianxin Gu
Jin-Hwan Kim
Srinivas Kodali
Jason Arnold Lotvin
Justin Keith Moran
Rosalind Pan
Avvari Krishna Prasad
Mark Edward Ruppen
Suddham Singh
Ling Chu
Scott Ellis Lomberk
Karen Kiyoko Takane
Nishith Merchant
Wei Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20211095A1 publication Critical patent/PE20211095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

la invencion se refiere a una composicion inmunogena que comprende moleculas de polisacarido O modificadas derivadas de lipopolisacaridos de E. coli y conjugados de estos. Se pueden preparar vacunas multivalentes mediante la combinacion de dos o mas composiciones inmunogenas monovalentes para diferentes serotipos de E. coli. En una forma de realizacion, las moleculas de polisacarido O modificadas son producidas por una bacteria recombinante que incluye un gen wzz
PE2021000227A 2018-08-24 2019-08-20 Composiciones de escherichia coli y metodos de estas PE20211095A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862722370P 2018-08-24 2018-08-24
US201862784940P 2018-12-26 2018-12-26
US201962881361P 2019-07-31 2019-07-31
PCT/IB2019/057025 WO2020039359A2 (en) 2018-08-24 2019-08-20 Escherichia coli compositions and methods thereof

Publications (1)

Publication Number Publication Date
PE20211095A1 true PE20211095A1 (es) 2021-06-14

Family

ID=68172237

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000227A PE20211095A1 (es) 2018-08-24 2019-08-20 Composiciones de escherichia coli y metodos de estas

Country Status (17)

Country Link
US (2) US11260119B2 (es)
EP (1) EP3840777A2 (es)
JP (1) JP2021534304A (es)
KR (1) KR102666639B1 (es)
CN (1) CN112566658A (es)
AU (1) AU2019325400B2 (es)
BR (1) BR112021002530A2 (es)
CA (1) CA3110134A1 (es)
CO (1) CO2021001926A2 (es)
IL (2) IL281094B2 (es)
MX (2) MX2021001182A (es)
PE (1) PE20211095A1 (es)
PH (1) PH12021550319A1 (es)
SG (1) SG11202101158TA (es)
TW (2) TWI782226B (es)
WO (1) WO2020039359A2 (es)
ZA (1) ZA202100469B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20220143910A (ko) * 2020-02-23 2022-10-25 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
MX2023003169A (es) * 2020-09-17 2023-03-27 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas.
PE20231934A1 (es) * 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
CA3215752A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
EP0413378B1 (en) 1989-08-18 1995-01-18 Akzo Nobel N.V. Escherichia coli vaccine
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
ATE178907T1 (de) 1992-05-06 1999-04-15 Harvard College Rezeptorbindende region des diphtherietoxius
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
PT616034E (pt) 1993-03-05 2005-02-28 Wyeth Corp Plasmideo para a producao de proteina crm e toxina da difteria
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
EP1039935A4 (en) 1997-02-28 2005-04-27 Univ Iowa Res Found USE OF NUCLEIC ACIDS CONTAINING NON-METHYLATED CpG DINUCLEOTIDES IN THE TREATMENT OF LIPOPOLYSACCHARIDE-ASSOCIATED ILLNESSES
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
NZ506603A (en) 1998-04-09 2002-10-25 Smithkline Beecham Biolog S Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2338093C (en) 1998-07-20 2010-11-30 Shousun C. Szu Vaccines against escherichia coli o157 infection
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CN101926993B (zh) 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
ATE422899T1 (de) 1998-12-21 2009-03-15 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
DK1141306T3 (da) 1998-12-23 2008-08-18 Id Biomedical Corp Streptococcus-antigener
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
NZ513841A (en) 1999-03-19 2001-09-28 Smithkline Beecham Biolog S Vaccine against Streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
IL145982A0 (en) 1999-04-19 2002-07-25 Smithkline Beecham Biolog Vaccines
JP2003504083A (ja) 1999-07-13 2003-02-04 メディミューン，インコーポレーテッド 供与体鎖相補ピリン・アドヘジンブロードベイストワクチン
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
CN1449446A (zh) 2000-06-20 2003-10-15 夏尔生化公司 链球菌抗原
AU2001271907A1 (en) 2000-07-07 2002-01-21 Medimmune, Inc. FimH adhesin proteins and methods of use
EP1349570B1 (en) 2001-01-04 2013-11-20 University Of Saskatchewan Enterohemorrhagic escherichia coli vaccine
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003054007A2 (en) 2001-12-20 2003-07-03 Shire Biochem Inc. Streptococcus antigens
NZ541969A (en) 2003-03-13 2008-01-31 Glaxosmithkline Biolog Sa Purifying pneumolysin from Streptococcus pneumoniae in a single chromatographic step by binding it to a hydrophobic interaction column in the presence of detergent and high salt
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP1781325A2 (en) 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
WO2006134423A2 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN113198012B (zh) 2005-04-08 2024-09-17 惠氏有限责任公司 多价肺炎球菌多糖－蛋白质缀合物组合物
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2687627A1 (en) 2007-05-22 2008-11-27 Basf Plant Science Gmbh Plants with increased tolerance and/or resistance to environmental stress and increased biomass production
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
TW201544119A (zh) 2009-06-22 2015-12-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
SG178035A1 (en) 2009-07-16 2012-03-29 Novartis Ag Detoxified escherichia coli immunogens
LT2493498T (lt) 2009-10-30 2017-05-25 Glaxosmithkline Biologicals Sa Staphylococcus aureus 5 tipo ir 8 tipo kapsulinių sacharidų gryninimas
CA2798381C (en) 2010-05-06 2020-10-06 Glycovaxyn Ag Capsular gram-positive bacteria bioconjugate vaccines
WO2012001004A1 (en) 2010-07-02 2012-01-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Fimh vaccine against urinary tract infections (uti)
WO2013164334A1 (en) 2012-05-04 2013-11-07 Universiteit Gent Escherichia coli vaccine
EP2859013B1 (en) 2012-06-12 2016-08-31 Fina Biosolutions LLC Differential functionalization of polymers with amino-oxy reagents for diagnostic assays
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
MX363511B (es) * 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
BR112015008052A2 (pt) 2012-10-12 2017-11-28 Glycovaxyn Ag célula hospedeira, métodos para produzir um glicoconjugado e para produzir uma proteína n-glicosilada, e, glicoconjugado
CA3125293A1 (en) 2012-11-07 2014-05-15 Glaxosmithkline Biologicals Sa Production of recombinant vaccine in e. coli by enzymatic conjugation
DK2935299T3 (da) 2012-12-20 2019-11-18 Pfizer Glycokonjugationsfremgangsmåde
JP6553517B2 (ja) 2013-01-17 2019-07-31 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｍｄｒ大腸菌特異的抗体
CA2919412A1 (en) 2013-07-26 2015-01-29 University Of Saskatchewan Methods for producing salmonella o-antigen capsules, compositions and uses thereof
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
BR112016007727A8 (pt) 2013-10-11 2018-01-30 Glycovaxyn Ag célula hospedeira, e, método para produzir uma proteína n-glicosilada.
CN110787290B (zh) 2014-01-21 2024-06-04 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US9700612B2 (en) 2014-02-24 2017-07-11 Glycovaxyn Ag Polysaccharide and uses thereof
CA2954087C (en) 2014-07-25 2023-09-19 Biosynth S.R.L. Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria
US20160015797A1 (en) 2014-08-06 2016-01-21 Pasteur Institute of Iran (IPI) VACCINE FOR UTI WITH TRUNCATED FORM OF FLAGELLIN (FliC) FROM ENTEROAGGREGATIVE ESCHERICHIA COLI FUSED WITH FimH PROTEIN
EP3193918A4 (en) 2014-09-18 2018-06-20 University of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
US20180000918A1 (en) 2015-01-14 2018-01-04 Washington University Vaccine compositions for use against enterotoxigenic escherichia coli
US10716839B2 (en) 2015-04-13 2020-07-21 University Of Maryland, Baltimore Compositions and methods for producing bacterial conjugate vaccines
EP3292146A1 (en) 2015-05-04 2018-03-14 Pfizer Inc Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EP3294761A4 (en) 2015-05-13 2019-04-03 University of Washington COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
EP3377098A1 (en) 2015-11-20 2018-09-26 Pfizer Inc Immunogenic compositions for use in pneumococcal vaccines
CA3053712A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2021087420A (ja) 2019-11-01 2021-06-10 ファイザー・インク Ｅｓｃｈｅｒｉｃｈｉａ ｃｏｌｉ組成物およびその方法
FI4090363T3 (fi) 2020-01-16 2024-09-25 Janssen Pharmaceuticals Inc FimH-mutantti, sen koostumuksia ja sen käyttö
KR20220143910A (ko) 2020-02-23 2022-10-25 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그의 방법
PE20231934A1 (es) 2020-10-27 2023-12-01 Pfizer Composiciones de escherichia coli y metodos de las mismas
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof

Also Published As

Publication number Publication date
US11260119B2 (en) 2022-03-01
KR20210049866A (ko) 2021-05-06
CO2021001926A2 (es) 2021-05-31
EP3840777A2 (en) 2021-06-30
AU2019325400A1 (en) 2021-02-18
WO2020039359A2 (en) 2020-02-27
BR112021002530A2 (pt) 2021-05-11
CA3110134A1 (en) 2020-02-27
PH12021550319A1 (en) 2021-10-04
AU2019325400B2 (en) 2024-04-04
JP2021534304A (ja) 2021-12-09
TWI831394B (zh) 2024-02-01
IL281094A (en) 2021-04-29
KR102666639B1 (ko) 2024-05-20
CN112566658A (zh) 2021-03-26
TWI782226B (zh) 2022-11-01
IL310402A (en) 2024-03-01
TW202023609A (zh) 2020-07-01
ZA202100469B (en) 2024-09-25
US20200061177A1 (en) 2020-02-27
IL281094B1 (en) 2024-03-01
US12128095B2 (en) 2024-10-29
WO2020039359A3 (en) 2020-04-09
MX2023013526A (es) 2024-01-08
US20220168410A1 (en) 2022-06-02
MX2021001182A (es) 2021-04-19
SG11202101158TA (en) 2021-04-29
TW202302140A (zh) 2023-01-16
IL281094B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
PE20211095A1 (es) Composiciones de escherichia coli y metodos de estas
CY1121535T1 (el) Πρωτεϊνικα κατασκευασματα uspa2 και χρησεις αυτων
BR112018003469A2 (pt) composição, método para induzir uma resposta imune a e. coli patogênica extraintestinal, e, processo para produzir uma composição.
EA201691478A1 (ru) Новый полисахарид и его применения
BR112017015789A2 (pt) vacina de vírus da influenza suína bivalente
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
AR105470A1 (es) Métodos para inducir una respuesta inmune
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
PE20180172A1 (es) Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
AR082952A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
CL2019001104A1 (es) Formulaciones de vacunas de glicoconjugados de expec.
BR112018076234A2 (pt) vacina contra o vírus da bronquite infecciosa
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
BR112018015453A2 (pt) vírus atenuado da bronquite infecciosa
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
EA201892003A1 (ru) Лечение атопического дерматита собак
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
AR116010A1 (es) Composiciones de escherichia coli y métodos de estas